This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Artivion (AORT), Incyte (INCY) and ClearPoint Neuro (CLPT)

Tipranks - Tipranks - Wed Jun 10, 8:12AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Artivion (AORT), Incyte (INCY) and ClearPoint Neuro (CLPT) with bullish sentiments.

Introducing TipRanks MCP for Agents

Artivion (AORT)

Lake Street analyst Frank Takkinen reiterated a Buy rating on Artivion today and set a price target of $45.00. The company’s shares closed last Monday at $20.39, close to its 52-week low of $19.36.

According to TipRanks.com, Takkinen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.8% and a 37.9% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Adagio Medical Holdings, TriSalus Life Sciences, and Tandem Diabetes Care. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Artivion with a $42.57 average price target, representing an 110.5% upside. In a report issued on June 1, Stifel Nicolaus also maintained a Buy rating on the stock with a $45.00 price target.

See the top stocks recommended by analysts >>

Incyte (INCY)

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Incyte, with a price target of $123.00. The company’s shares closed last Monday at $100.64.

According to TipRanks.com, Willey is a 4-star analyst with an average return of 5.8% and a 42.6% success rate. Willey covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Janux Therapeutics Inc, and Syndax Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $110.06 average price target, a 7.1% upside from current levels. In a report released yesterday, TipRanks – Anthropic also upgraded the stock to Buy with a $114.00 price target.

ClearPoint Neuro (CLPT)

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on ClearPoint Neuro today and set a price target of $16.00. The company’s shares closed last Monday at $13.38.

According to TipRanks.com, Stephan is a 3-star analyst with an average return of 2.1% and a 40.2% success rate. Stephan covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Alphatec Holdings, and TransMedics Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ClearPoint Neuro with a $22.00 average price target, implying a 66.8% upside from current levels. In a report issued on May 29, Lake Street also reiterated a Buy rating on the stock with a $30.00 price target.

Read More on AORT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).